The CEO foresees a "snowball effect" of life sciences companies coming to Dallas, but a couple things need to happen first.

Michael Breen, CEO of GT Biopharma (GTBP), a clinical-stage biotech company, stressed that point with TheStreet Pro’s Chris ...

Few, if any, institutions aiding St. Louis entrepreneurs can match BioGenerator's bang for the buck. {{description}} Email ...

Unexpected delays, infighting and a staffing crisis are fueling investors’ unease.

RA Capital Management’s Peter Kolchinsky says the companies that survived the industry’s 2021 rout are thriving—and looking ...

A Nobel laureate, he identified an enzyme that cuts DNA, laying the groundwork for milestones in scientific research and ...

French biotech company Abivax SA started the year with a market value of less than $500 million. After a meteoric rally, it’s ...

China's Sichuan Kelun-Biotech Biopharmaceutical (6990.HK) said Thursday night it would license an experimental cancer ...

A Pfizer-backed biotech landed $120M, embattled Kala Bio has secured a new CEO, and Akebia Therapeutics bought a rare kidney ...

Fintel reports that on December 8, 2025, UBS maintained coverage of Legend Biotech Corporation - Depositary Receipt (NasdaqGS ...

PTC’s strong third quarter and breakout Sephience launch may help explain why one life-sciences fund is quietly upping its ...

NDAA package revives stalled measures on US outbound investment and biotech, signalling Capitol Hill’s hardened stance ...